Replibio: Intends to transfer 48.4213% equity of Zhongdie Biotechnology.

RepuBio announced that the company plans to transfer 48.4213% equity of its holding subsidiary Zhongan Bio to Jiangxi Twin Biology Technology Co., Ltd. for a transaction price of 115 million yuan. After the completion of this transaction, the company will hold 20% equity of Zhongan Bio, and Zhongan Bio will no longer be included in the company's consolidated financial statements. This transaction does not constitute a related party transaction, nor does it constitute a major asset restructuring, and it still needs to be reviewed by the shareholders' meeting. The purpose of this transaction is to deepen strategic cooperation with breeding group customers and optimize asset and business structure.